Skip to content

Osteoarthritis Pipeline Seems Strong With 130+ Key Pharma Firms Actively Working within the Therapeutics Phase

PRESS RELEASE

Revealed January 26, 2023

DelveInsight’s, “Osteoarthritis Pipeline Perception, 2022,” report supplies complete insights about 130+ firms and 130+ pipeline medication within the Osteoarthritis pipeline panorama. It covers the Osteoarthritis pipeline drug profiles, together with scientific and nonclinical stage merchandise. It additionally covers the Osteoarthritis pipeline therapeutics evaluation by product sort, stage, route of administration, and molecule sort. It additional highlights the inactive pipeline merchandise on this house.

Within the Osteoarthritis Pipeline report, an in depth description of the drug is given which incorporates the mechanism of motion of the drug, scientific research, Osteoarthritis NDA approvals (if any), and product improvement actions comprising the know-how, Osteoarthritis collaborations, licensing, mergers and acquisition, funding, designations, and different product-related particulars.

Key takeaways from the Osteoarthritis Pipeline Perception Report

  • DelveInsight’s Osteoarthritis Pipeline report depicts a sturdy house with 130+ energetic gamers working to develop 130+ pipeline therapies for Osteoarthritis.
  • The main Osteoarthritis Firms similar to Biosplice Therapeutics, Gilead Sciences, Flexion Therapeutics, GlaxoSmithKline, Levicept, Arthrogen, Personalised Stem Cells, Peptinov, Asahi Kasei Pharma, Taiwan Bio Therapeutics, OliPass Company, Bioventus, Medipost, Moebius Medical, ReqMed, TissueTech, Novartis, AstraZeneca, Biosplice Therapeutics, Cynata Therapeutics, Bone Therapeutics SA, Regeneron Prescription drugs, Techfields Pharma, Ampio Prescription drugs, Taiwan Liposomal Firm, Ok-STEMCELL, Stempeutics, Levolta Prescription drugsand others.
  • Promising Osteoarthritis Therapies similar to V120083, Naproxen, EP-104IAR, Hyalgan, SI-613, Oral Calcitonin, APPAand others
  • The Osteoarthritis Firms and lecturers are working to evaluate challenges and search alternatives that would affect R&D Osteoarthritis. The Osteoarthritis pipeline therapies below improvement are targeted on novel approaches to deal with/enhance Osteoarthritis.

To discover extra data on the most recent breakthroughs within the Osteoarthritis Pipeline therapy panorama of the report, click on right here @ Osteoarthritis Pipeline Outlook

Osteoarthritis Overview

Osteoarthritis (OA) is the commonest type of arthritis. Some individuals name it degenerative joint illness or “put on and tear” arthritis. It happens most ceaselessly within the fingers, hips, and knees. Osteoarthritis is probably to have an effect on the joints that bear most of weight, such because the knees and ft. Joints that the particular person makes use of loads in on a regular basis life, such because the joints of the hand, are additionally generally affected. The primary signs of osteoarthritis are ache and typically stiffness within the affected joints. The ache tends to be worse when the particular person strikes the joint or on the finish of the day. Osteoarthritis is a number one explanation for incapacity and supply of societal price in older adults. With an growing old and more and more overweight inhabitants, this syndrome is changing into much more prevalent than in earlier a long time.

Latest Breakthroughs of Osteoarthritis Remedy Panorama

  • In January 2021 Apollomics, Inc., an revolutionary biopharmaceutical firm dedicated to the invention and improvement of mono- and combination- oncology therapies, and GlycoMimetics introduced APL-106 (uproleselan) has been granted Breakthrough Remedy Designation (BTD) from the China Nationwide Medical Merchandise Administration (NMPA) Heart for Drug Analysis (CDE) for the therapy of relapsed/refractory acute myeloid leukemia (AML).
  • In January 2022, Astex Prescription drugs, Inc. introduced that the European Fee (EC) has granted orphan-drug designation (ODD) to the oral fastened dose mixture of decitabine and cedazuridine (ASTX727) for the therapy of Acute Myeloid Leukemia (AML).
  • In April 2021, Ampio Prescription drugs introduced that it had acquired a constructive response from the US Meals and Drug Administration (FDA) on its plans for its AP-013 Section III trial for the intra-articular injection of Ampion, its novel anti-inflammatory, for sufferers affected by extreme osteoarthritis of the knee (OAK).
  • In April 2021, Biosplice Therapeutics introduced the execution of a licensing settlement that grants Samil the fitting to develop and solely commercialize lorecivivint (SM04690) for the therapy of knee osteoarthritis (“OA”) within the Republic of Korea.
  • In April 2021, Eupraxia Prescription drugs introduced that it has entered into an settlement (the “CTO Settlement”) with NBCD A/S (“NBCD”) to conduct Eupraxia’s EP-104IAR Section 2 scientific trial that may provoke later this yr.
  • In October 2020, Merck KGaA entered into an out-licensing settlement with Novartis for the event of an osteoarthritis clinical-stage programme. Underneath the phrases of the deal, Merck will out-license M6495 to Novartis for additional analysis in osteoarthritis sufferers.
  • In September 2020, Sorrento Therapeutics launched constructive Section 1b trial information (clinicaltrials.gov NCT03542838) of resiniferatoxin (RTX) within the discount of OsteoArthritis (OA) knee ache.
  • X0002 is a brand new anti-inflammatory drug that acts as an inhibitor of Cyclooxygenase. It’s presently within the Section III stage of improvement for Osteoarthritis and is being developed by Techfields Pharma.
  • In July 2020, the FDA granted the Quick Observe Designation to X0002 for Knee Osteoarthritis and the low again.

Request a pattern and uncover the latest advances in Osteoarthritis Ongoing Medical Trial Evaluation and Drugs, click on right here @ Osteoarthritis Remedy Panorama

Osteoarthritis Rising Medicine Profile

Lorecivivint: Biosplice Therapeutics

Lorecivivint (SM04690) is a small-molecule CLK/DYRK1A inhibitor that modulates Wnt and inflammatory pathways and is in improvement as a possible disease-modifying osteoarthritis drug. Car-controlled preclinical information recommend that lorecivivint has a twin mechanism of motion with three potential results on joint well being: discount of irritation, slowing of cartilage breakdown, and technology of cartilage. The drug is presently in Section III stage of scientific trial analysis to deal with sufferers affected by osteoarthritis

CYP 004: Cynata Therapeutics

Cynata’s CYP-004 MSC product is the topic of a Section III scientific trial being sponsored by the College of Sydney and funded by an Australian Authorities Nationwide Well being and Medical Analysis Council (NHMRC) aggressive Mission Grant along with in-kind contributions from taking part establishments . Cynata will provide Cymerus MSCs to be used within the trial and won’t be required to contribute any money to fund the venture. The scientific trial began in late 2020 and is entitled Stem Cells as a symptom- and strUcture-modifying Remedy for medial tibiofemoral OsteoaRthritis (SCUlpTOR): a randomized placebo-controlled trial

JTA-004: Bone Therapeutics

JTA-004 is Bone Therapeutics’ subsequent technology of intra-articular injectable, which is presently in part III improvement for the therapy of osteoarthritic ache within the knee. Consisting of a novel patented mixture of plasma proteins, hyaluronic acid – a pure element of knee synovial fluid, and a fast-acting analgesic, JTA-004 intends to supply added lubrication and safety to the cartilage of the arthritic joint and to alleviate osteoarthritic ache . In a part II examine involving 164 sufferers, JTA-004 confirmed an improved ache reduction at 3 and 6 months in comparison with Hylan GF 20, the worldwide market chief in osteoarthritis therapy.

SMUP-IA-01: Medipost

SMUP-IA-01, SMUP allogeneic umbilical twine blood-derived mesenchymal stem cells, is presently below improvement for the therapy and prevention of Osteoarthritis. In SMUP-IA-01’s part I scientific trials in Korea, 12 sufferers with knee osteoarthritis got a single injection into their knee joint cavity at Seoul Nationwide College Hospital. The response to the drug was then evaluated for six months, and the outcomes had been proven to show the protection and enchancment of joint perform and ache.

TTAX03: Tissue Tech

TTAX03 is a sterile, lyophilized and micronized particulate human Amniotic and umbilical twine co-product manufactured utilizing aseptic processing adopted by terminal sterilization by gamma irradiation in compliance with present Good Tissue Practices (cGTP) and present Good Manufacturing Practices (cGMP) to protect extracellular matrices and development elements/cytokines therein with none residing cells. TTAX03 is presently being investigated in Section II stage of improvement for the therapy of sufferers with knee osteoarthritis

Osteoarthritis Pipeline Therapeutics Evaluation

There are approx. 130+ key firms that are growing the Osteoarthritis rising therapies. The Osteoarthritis firms which have their Osteoarthritis drug candidates in probably the most superior stage, ie part III embody Biosplice Therapeutics

Scope of the Osteoarthritis Pipeline Report

  • Protection – International
  • Osteoarthritis Firms- Biosplice Therapeutics, Gilead Sciences, Flexion Therapeutics, GlaxoSmithKline, Levicept, Arthrogen, Personalised Stem Cells, Peptinov, Asahi Kasei Pharma, Taiwan Bio Therapeutics, OliPass Company, Bioventus, Medipost, Moebius Medical, ReqMed, TissueTech, Novartis, AstraZeneca, Biosplice Therapeutics, Cynata Therapeutics, Bone Therapeutics SA, Regeneron Prescription drugs, Techfields Pharma, Ampio Prescription drugs, Taiwan Liposomal Firm, Ok-STEMCELL, Stempeutics, Levolta Prescription drugsand others.
  • Osteoarthritis Therapies- V120083, Naproxen, EP-104IAR, Hyalgan, SI-613, Oral Calcitonin, APPAand others.
  • Osteoarthritis Pipeline Segmentation: Product Sort, Molecule Sort, Route of Administration, Mechanism of Motion

Desk of Contents

  1. Introduction
  2. Osteoarthritis Govt Abstract
  3. Osteoarthritis: Overview
  4. Osteoarthritis Pipeline Therapeutics
  5. Osteoarthritis Pipeline Therapeutic Evaluation
  6. Osteoarthritis–DelveInsight’s Analytical Perspective
  7. Late Stage Merchandise (Section III)
  8. Lorecivivint: Biosplice Therapeutics
  9. Drug profiles within the detailed report…..
  10. Mid Stage Merchandise (Section II)
  11. TTAX03: Tissue Tech
  12. Drug profiles within the detailed report…..
  13. Early Stage Merchandise (Section I)
  14. GLPG-0555: Gilead Sciences
  15. Drug profiles within the detailed report…..
  16. Preclinical Stage Merchandise
  17. Protego-PD: Plakous Therapeutics
  18. Drug profiles within the detailed report…..
  19. Inactive Merchandise
  20. Osteoarthritis Key Firms
  21. Osteoarthritis Key Merchandise
  22. Osteoarthritis- Unmet Wants
  23. Osteoarthritis- Market Drivers and Obstacles
  24. Osteoarthritis- Future Views and Conclusion
  25. Osteoarthritis Analyst Views
  26. Osteoarthritis Key Firms
  27. Appendix

Acquired Desires? Discover out the associated data on Osteoarthritis Mergers and acquisitions, Osteoarthritis Licensing Actions @ Osteoarthritis Rising Medicine, and Latest Traits

Associated Reviews- Stem Cell Market | Asperger Syndrome Market

about us

DelveInsight is a Enterprise Consulting and Market analysis firm, offering knowledgeable enterprise options for the healthcare area and providing quintessential advisory companies within the areas of R&D, Technique Formulation, Operations, Aggressive Intelligence, Aggressive Landscaping, and Mergers & Acquisitions.

Media Contact
Firm Title: DelveInsight
Contact Individual: Yash Bhardwaj
E-mail: ship e-mail
Cellphone: 9193216187
Handle:304 S. Jones Blvd #2432
Metropolis: Las Vegas
Standing: NV 89107
Nation: United States
Web site: https://www.delveinsight.com/consulting/due-diligence-services

Leave a Reply

Your email address will not be published. Required fields are marked *